Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)

Other Clinical Trial

Official title: A Phase 1 Study to Evaluate the Bioequivalence Between DopaSnap® (Carbidopa/Levodopa 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet and to Evaluate the Food-Effect of DopaSnap® in Normal Healthy Volunteers

Status Completed

Clinical Trial Summary

This will be a single center, bioequivalence and food-effect, open-label study designed to be conducted in three sequential parts:

Clinical Trial Description

This will be a single center, bioequivalence and food-effect, open-label study designed to be conducted in three sequential parts:

• Part I: bioequivalence, food-effect, randomized, open-label, single dose, 3-period, 6-sequence, crossover design.

• Part II: multiple-dose (every 4 hours), open-label, 1-period design.

• Part III: multiple-dose (every 2 hours), open-label, 1-period design. ;

Related Conditions & MeSH terms

• Other

• NCT number: NCT04236921
• Study type: Interventional
• Source: Riverside Pharmacueticals Corporation
• Status: Completed
• Phase: Phase 1
• Start date: July 15, 2019
• Completion date: December 1, 2019